synergy nash tirzepatide Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis

This data helps your healthcare provider make informed adjustments to your protocol, whether that means slowing escalation, adding supportive interventions, or confirming that your current dose is well-tolerated

You may also hear the term infiltrative lipoma, what some veterinarians call lipomas that grow in between muscle layers

Notably, in the SURMOUNT-1 DXA substudy, visceral fat mass was reduced by 40.1% with tirzepatide compared with 7.3% with placebo [58]

Gastrointestinal adverse reactions are the most frequently reported effects of tirzepatide, directly related to its effect on gastric emptying and gut motility